STING1 and neoplasm: Given these promising results, STING agonists, combined with anti-PD1 and/or anti-CTLA4 therapy, have entered clinical trials in multiple ICI refractory solid tumors, including PDAC, to identify if enhancing chemokine secretion intra-tumorally will result in an increased anti-tumor response [179].